Drug Trial Radar · NCT02920229
68Ga-PSMA HBED-PET/CT in the Evaluation of the Biochemical Relapse in Patients With a History of Prostate Cancer Radically Treated
Last checked: Nov 19, 2026Latest source record: Jan 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,230
Actual
Start
Nov 2015
Primary completion
Oct 9, 2020
Study completion Oct 9, 2020
Sponsor
- Lead sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 30, 2016
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- Male only, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Single-center, prospective, diagnostic trial in radically treated patients with biochemical recurrence of prostate cancer. Patients with radically treated prostate cancer with biochemical relapse and negativity of all traditional morphological and functional imaging (transrectal ultrasound, bone scan, 18F-FMC PET/CT, CT/MRI) or doubtful imaging of 2-deoxy-2-\[fluorine-18\] (18F)-fluoromethylcholine (FMC) PET/CT will receive a Gallio-68 (68Ga)- Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET)/Computed Tomography (CT) scan.
Conditions
- 68Ga-PSMA HBED-PET/CT
- Prostate Cancer
Interventions
68Ga- PSMADrug
100-200 MBq of 68Ga-PSMA will be injected intravenously prior to perform the PET/CT
Primary outcomes
What the sponsor says the trial is designed to measure.
- the ratio between the number of 68Ga-PSMA PET/CT positive patients and the number of prostate cancer patients with biochemical relapse and negative standard imagingTime frame: up to 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Irst Irccs
Meldola, FC, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.